Institute of Cancer Research - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
81
About the Report
About the Report
Summary
Institute of Cancer Research (ICR), a subsidiary of University of London is a research institute that offers cancer research and education programs. The institute conducts research and develops new therapies for the treatment of cancer including breast and lung cancer. It offers various postgraduate and higher education programs in several streams. ICR conducts research services in areas of breast cancer, clinical studies, molecular pathology, genetics and epidemiology, radiotherapy and imaging, among others. The institute operates through collaborations with cancer research centers, and healthcare organizations. ICR is headquartered in London, the UK.
Institute of Cancer Research-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Institute of Cancer Research, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Institute of Cancer Research, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Institute of Cancer Research, Medical Devices Deals, 2012 to YTD 2018 10
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deal Details 13
Private Equity 13
DRI Capital Acquires Partial Royalty Rights of Zytiga from Institute of Cancer Research 13
Partnerships 14
Cellcentric and Institute of Cancer Research Enter into Research Agreement 14
Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 15
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 16
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 18
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 19
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 20
Licensing Agreements 22
Merck Enters into Licensing Agreement with Institute of Cancer Research and Cancer Research UK 22
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 23
Institute of Cancer Research Enters Into Licensing Agreement With Dotmatics For Informatics Platform 24
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 25
Institute of Cancer Research-Key Competitors 27
Institute of Cancer Research-Key Employees 28
Institute of Cancer Research-Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Government and Public Interest 30
Sep 06, 2018: Study finds immunotherapy may treat certain prostate cancers 30
Sep 04, 2018: Early research shows immunotherapy's potential for one type of aggressive prostate cancer 31
Jul 04, 2018: UK study finds triple therapy can prevent breast cancer relapse 32
Jun 14, 2018: Gene testing could identify men with prostate cancer who may benefit from immunotherapy 33
Jun 05, 2018: Stunting cell 'antennae' could make cancer drugs work again 36
Apr 16, 2018: Scientists uncover 80 potential lines of attack against prostate cancer 38
Mar 07, 2018: To halt breast cancer's spread, scientists block amino acid found in asparagus 40
Mar 05, 2018: New class of drugs effective against one of the toughest cancers to treat 41
Jan 24, 2018: Viral gene therapy could improve results from breast reconstruction surgery after cancer treatment 42
Jan 03, 2018: Virus could treat brain tumours by boosting immune system 44
Nov 16, 2017: ICR responds to NICE approval of new breakthrough drugs on the NHS for women with advanced breast cancer 47
Nov 07, 2017: NCRI 2017: Big data analysis predicts risk of radiotherapy effects 48
Sep 22, 2017: New treatment approach for rare type of triple negative breast cancers identified 49
Sep 10, 2017: Merck 'Grant for Oncology Innovation' awards recognize recipients for pushing boundaries in oncology research 51
Sep 05, 2017: New approach could better predict breast cancer risk due to family history 52
Aug 29, 2017: Bowel cancer study reveals impact of mutations on protein networks 54
Aug 02, 2017: Targeted radiotherapy limits side effects of breast cancer treatment 56
Jul 10, 2017: Scientists call for better use of chemical tools to improve cancer drug discovery 58
Jul 10, 2017: ICR awarded GBP30 million towards new Centre for Cancer Drug Discovery 59
May 30, 2017: Pioneering genetic research into myeloma is spearheading our search for new treatments 60
May 29, 2017: New genetic cause of kidney cancer in children discovered 61
May 16, 2017: Scientists build molecule to disrupt cancer protein 62
Mar 27, 2017: Largest ever brain cancer study reveals new secrets to inherited risk 63
Mar 27, 2017: ICR scientists awarded GBP1.5m precision medicine funding for targeted, less toxic childhood cancer treatments 65
Jan 12, 2017: Scientists discover powerful new inhibitor of cancer stress signal 66
Product News 68
Dec 05, 2017: Breast, bowel and other cancers could be targeted by new drug type 68
Sep 04, 2018: New REVOLVER technique can predict how cancer will advance 69
Aug 02, 2018: Super-resolution MRI to aid radiotherapy for lung cancer decisions 70
Jun 06, 2017: New chemotherapy approach offers breast cancer patients a better quality of life 71
Apr 30, 2018: Targeting chemotherapy with genetic testing provides effective treatment for women with aggressive breast cancer 72
Apr 19, 2018: Scans could guide drug treatment in breast cancer 75
Apr 04, 2017: Secrets of genetic risk revealed in largest ever brain cancer study 76
Jan 30, 2018: Blood test could indicate which patients will respond to immunotherapy 78
Other Significant Developments 79
Sep 13, 2018: Viruses show new promise in treating cancer 79
Appendix 81
Methodology 81
About GlobalData 81
Contact Us 81
Disclaimer 81
List of Figure
List of Figures
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Institute of Cancer Research, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Institute of Cancer Research, Pharmaceuticals & Healthcare, Key Facts 2
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Institute of Cancer Research, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Institute of Cancer Research, Deals By Therapy Area, 2012 to YTD 2018 9
Institute of Cancer Research, Medical Devices Deals, 2012 to YTD 2018 10
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
DRI Capital Acquires Partial Royalty Rights of Zytiga from Institute of Cancer Research 13
Cellcentric and Institute of Cancer Research Enter into Research Agreement 14
Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 15
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 16
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 18
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 19
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 20
Merck Enters into Licensing Agreement with Institute of Cancer Research and Cancer Research UK 22
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 23
Institute of Cancer Research Enters Into Licensing Agreement With Dotmatics For Informatics Platform 24
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 25
Institute of Cancer Research, Key Competitors 27
Institute of Cancer Research, Key Employees 28
Institute of Cancer Research, Other Locations 29
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.